CD8A and melanoma: Using a library of pHLA class I multimers and artificial APCs, we were able to determine the specificity of 12.2 ± 7.3% (mean ± SD, max 25.9%, min 4.6%) of the CD8+ TILs from eight melanoma patients toward 3.1 ± 2.0 (mean ± SD, max 7, min 1) previously known and novel peptides derived from shared antigens across HLA-A, B, and C. Notably, the maximum accumulative total percentage of multimer-positive CD8+ T cells was 25.9% (M31 TILs) (Figure 6).